Abstract
To determine the tolerability of a glycine (Gly)-containing acetylsalicylic acid (ASA) preparation (Gly-ASA), investigators selected 1135 patients already receiving longterm antiplatelet therapy for a noninterventional trial of Gly-ASA 50 to 300 mg daily. After an average treatment period of 42.6 days, tolerability rating scores and the frequency of 5 gastrointestinal (Gl) complaints were compared with those reported for any previous treatment, including plain ASA. After treatment with Gly-ASA, the mean percentage of patients without Gl complaints increased more than 2-fold, from 28.2% to 60.6%. Furthermore, the mean percentage of patients reporting any Gl symptoms as “always” present decreased from 8.5% to 0.5%. Gly-ASA tolerability was rated “excellent” or “good” by 98% of the patients. In 10 patients (0.9%), Gly-ASA treatment was terminated prematurely due to Gl intolerance (n=4) and nonmedication-related causes (n=6). With respect to long-term treatment compliance, the improved tolerability profile observed with this Gly-ASA preparation indicates an important advantage over nonglycine-containing ASA alternatives.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Handin RI. Anticoagulant, fibrinolytic, and antiplatelet therapy. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, eds.Harrison’s Principles of Internal Medicine. 14th ed. New York, NY: McGraw-Hill; 1998:744–747.
Sweetman SC, ed.Martindale: The Complete Drug Reference. 33rd ed. London: Pharmaceutical Press; 2002:14–18.
Rapson HDC, Singleton DO, Stuart ACE, Taylor MR Physico-chemical studies of aspirin with glycine.J Pharmacy Pharmacol. 1959;(suppl 11):210–217.
Schnell O, Lang E, Berthold H. On the platelet aggregation inhibiting and analgesic activities of acetylsalicylic acid.Arzneim Forsch/Drug Res. 1980;3011:1917–1922.
Brandon RA, Eadie MJ, Curran ACW, et al. A new formulation of aspirin: bioavailability and analgesic efficacy in migraine attacks.Cephalalgia. 1986;6:19–27.
Schürer M, Bias-Imhoff U, Schulz HU, et al. Lack of influence of glycine on the single dose pharmacokinetics of acetylsalicylic acid in man.Int J Clin Pharmacol Ther. 1996;34:282–287.
Baumann J, Kopp H. Zur frage des iatrogenen ulcus ventriculi et duodeni.Zeitschr Allgemeinmed. 1977;28:1723–1729.
Knote G, Vielsäcker H, Mappes G. Verträglichkeit Verschiedener Acetylsalicylsäurepräparate in der Thromboseprophylaxe.Med Klin. 1976;71:1235–1238.
Müller P, Dammann HG, Bergholt H, Simon B. Influence of glycine on the gastroduodenal tolerability of acetylsalicylic acid: an endoscopically controlled double-blind study in healthy volunteers.Arzneim. Forsch/Drug Res. 1991;41:812–814.
Victor N, Schäfer H, Nowak H, et al. Arzneimittelforschung nach der Zulassung. Bestandsaufnahme und Perspektiven. In: Überla K, Rienhoff O, Victor N, eds.Medizinische Informatik und Statistik. Berlin: Springer Verlag; 1991:16884.
Empfehlungen zur Planung, Durchführung und Auswertung von Anwendungsbeobachtungen vom 12. November 1998. Bundesanzeiger 229 v. 04.12.1998.
Weichert W, Meents H, Abt K, et al. Acetylsalicylic acid-reocclusion-prophylaxis after angioplasty (ARPA-Study): a randomized double-blind trial of two different dosages of ASA in patients with peripheral occlusive arterial disease.VASA. 1994;23:57–65.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kusche, W., Paxinos, R., Haselmann, J. et al. Acetylsalicylic acid tablets with glycine improve long-term tolerability in antiplatelet drug therapy. Adv Therapy 20, 237–245 (2003). https://doi.org/10.1007/BF02849852
Issue Date:
DOI: https://doi.org/10.1007/BF02849852